Although it is crucial to ensure a sufficient surgical margin for a malignant neoplasm, we sometimes struggle to achieve this goal using a minimally invasive approach because it is difficult to palpate the tumor adequately via the small skin incision. To overcome this issue, we adopted a preoperative simulation method for a patient undergoing a right upper lobe and a posterior segmentectomy of the lower lobe (extended lobectomy) and obtained successful results. The discrepancy between the virtual and the actual surgical margins was 5 mm.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1510/mmcts.2022.038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Approach to the Patient with Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
J Clin Endocrinol Metab
January 2025
Department of Otolaryngology-Head and Neck Surgery, Beilinson Hospital, Rabin Medical Center.
Thyroid lobectomy has gained increasing popularity over the past decade as a treatment for differentiated thyroid cancer (DTC), largely due to a rise in the diagnosis of low-risk cancers and evidence showing no benefit from radioiodine in low-risk disease. Multiple studies have confirmed lobectomy as an effective and safe option. Its advantages over total thyroidectomy include lower complication rates and a reduced need for lifelong levothyroxine (LT4) therapy.
View Article and Find Full Text PDFCase report: Combination therapy for hepatocellular carcinoma with inferior vena cava or right atrial tumor thrombus in the era of combined targeted and immunotherapeutic agents.
Front Oncol
December 2024
Department of Hepatobiliary and Pancreatic Surgery I, General Surgery Center, The First Hospital of Jilin University, Changchun, China.
Article Synopsis
- Primary liver cancer, mainly hepatocellular carcinoma (HCC), is a major cause of cancer deaths, and tumor thrombus (TT) in major vessels worsens patient outcomes.
- Four male HCC patients (average age 57) with TT in the inferior vena cava or right atrium underwent surgery to remove the tumors, followed by targeted and immunotherapy.
- All cases show positive outcomes post-treatment, with some patients remaining disease-free for up to 74 months, suggesting that combining surgery with therapy could improve survival rates in advanced HCC patients.
Long-term follow-up of combination therapy with pembrolizumab and anlotinib in thoracic SMARCA4-deficient undifferentiated tumor: a case report and molecular features.
Front Oncol
December 2024
Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital(Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China.
Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs), recently recognized as a rare malignancy described in the 5th edition of the World Health Organization Classification of Tumors, are characterized by an inactivating mutation in SMARCA4, most commonly found in the mediastinum of male smokers. Despite the aggressive nature and poor prognosis associated with these tumors, which have a median survival time of approximately 4-7 months, no standardized treatment guidelines are currently established. There are currently no reported cases of extended progression-free survival (PFS) in SMARCA4-UT patients treated with surgery and immunotherapy.
View Article and Find Full Text PDFThe prognosis and treatment consideration for non-small cell lung carcinoma patients with tumor size of >2.0-3.0 cm and visceral pleural invasion: a SEER-based study.
Transl Cancer Res
November 2024
Department of Thoracic Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Background: Lung cancer is the most prevailing oncological disease worldwide. Visceral pleural invasion (VPI) has been proven to be a poor prognosis factor for early-stage non-small cell lung carcinoma (NSCLC) patients. However, there remains some debate regarding whether NSCLC patients with tumor size (TS) ranging from >2.
View Article and Find Full Text PDFEffectiveness of the enhanced recovery after surgery (ERAS) program after lobectomy for lung cancer: a single-center observational study using propensity score matching in Vietnam.
J Thorac Dis
November 2024
Faculty of Medical Management, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
Background: Postoperative complications and extended length of stays (LOS) following lobectomy for non-small cell lung cancer (NSCLC) remain significant healthcare and economic burdens, especially in developing countries with limited resources. This study evaluated the effectiveness of enhanced recovery after surgery (ERAS) protocols in addressing these issues.
Methods: This observational study compared two groups of patients, utilizing a prospective arm for ERAS and a retrospective arm for routine care.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!